For the Inventor, By the Inventor

Enter assignee name

Monrovia, CA, United States of America

Xencor, Inc.

USPTO Granted Patents = 216

CIPO Patents = 16

EPO Patents = 48

Trademarks = 5

Forward Citations = 3,823

Loading Chart...

Loading Chart...

107 inventors (with patents filed for the assignee):

John R Desjarlais (171 out of 172 patents)

Matthew J Bernett (98 out of 100 patents)

Gregory Alan Lazar (84 out of 94 patents)

4. Gregory L Moore (79 out of 80 patents)

5. Sher Bahadur Karki (68 out of 68 patents)

6. Rumana Rashid (54 out of 54 patents)

7. Seung Yup Chu (51 out of 51 patents)

8. Omid Vafa (33 out of 37 patents)

9. Wei Dang (32 out of 32 patents)

10. Robert J Hayes (32 out of 33 patents)

11. Bassil I Dahiyat (30 out of 37 patents)

12. Umesh Muchhal (25 out of 26 patents)

13. Rajat Varma (21 out of 21 patents)

14. Arthur J Chirino (20 out of 20 patents)

15. Sung-Hyung Lee (18 out of 18 patents)

Core Competencies:

Heterodimeric Antibodies

Fc Fusion Proteins

Bispecific Antibodies

NKG2D Antigen Binding

CD3 Binding Agents

IL-15/IL-15RA Fusion

Prostate Specific Membrane Antigen

Tumor Antigens

Optimized Antibody Variants

Immune Checkpoint Inhibitors

CD38 Binding Agents

TIM-3 Targeted Proteins

216 patents: Sort by Forward Citations

1. 12448423 - Targeted heterodimeric Fc fusion proteins containing NKG2D antigen binding domains (2025-10-21),

2. 12415849 - Heterodimeric proteins (2025-09-16),

3. 12404329 - Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 (2025-09-02),

4. 12398207 - Heterodimeric antibodies that bind CD3 and CLDN6 (2025-08-26),

5. 12378326 - Anti-CD28 x anti-PSMA antibodies (2025-08-05),

6. 12378313 - Bispecific binding agents binding to CLDN18.2 and CD3 (2025-08-05),

7. 12365743 - Anti-CD28 x anti-PSMA antibodies (2025-07-22),

8. 12359002 - Heterodimeric antibodies that bind CD3 and tumor antigens (2025-07-15),

9. 12239688 - IL-15/IL-15RA heterodimeric Fc fusion proteins and uses thereof (2025-03-04),

10. 12234270 - IL-12 heterodimeric Fc-fusion proteins (2025-02-25),

11. 12215165 - Fc variants with altered binding to FcRn (2025-02-04),

12. 12180302 - Heterodimeric antibodies that bind fibroblast activation protein (2024-12-31),

13. 12152076 - Bispecific and monospecific antibodies using novel anti-PD-1 sequences (2024-11-26),

14. 12139525 - Targeted heterodimeric Fc fusion proteins containing IL-15 IL-15alpha and antigen binding domains (2024-11-12),

15. 12129309 - Heterodimeric antibodies that bind CD3 and CD38 (2024-10-29),

Xencor, Inc. is a biopharmaceutical company specializing in the development of engineered monoclonal antibodies for the treatment of severe diseases. Their unique technology platform enables the creation of antibody drugs with enhanced therapeutic properties, improving patient outcomes. Xencor's focus areas include oncology, autoimmune disorders, and allergic diseases. Through their innovative approach, Xencor aims to transform the lives of patients by advancing the understanding and application of monoclonal antibody therapeutics.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 16 2025

216 Patents

#2 in Monrovia, CA

#422 in California

#1,856 in US

#3,828 in the World

Monrovia, CA, United States of America

Xencor, Inc.

Forward Citations = 3,823

107 inventors:

John R Desjarlais (171 out of 172 patents)

Matthew J Bernett (98 out of 100 patents)

Gregory Alan Lazar (84 out of 94 patents)

4. Gregory L Moore (79 out of 80 patents)

5. Sher Bahadur Karki (68 out of 68 patents)

Please report any incorrect information to support@idiyas.com

Loading…